OptimizeRx Corp. (OPRX) News & Corporate Actions | Announcements, Board Meetings, Splits, Bonuses, Rights Issues

{
  "main_header": {
    "sid": 1158609,
    "name": "OptimizeRx Corp.",
    "stock_name": "OptimizeRx Corp.",
    "full_name": "OptimizeRx Corp.",
    "name_url": "stocks-analysis/optimizerx-corp",
    "exchange": 210,
    "exchangecode": "NAS",
    "country_id": 2,
    "currency": "USD",
    "cmp": "14.65",
    "chg": 0.54,
    "chgp": "3.83%",
    "dir": 1,
    "prev_price": "14.11",
    "mcapval": "339.55",
    "mcap": "Micro Cap",
    "scripcode": "",
    "symbol": "",
    "ind_name": "Software Products",
    "ind_code": 3310,
    "indexname": "S&P 500",
    "isin": "US68401U2042",
    "curr_date": "Dec 04",
    "curr_time": "",
    "bse_nse_vol": "287.04 k",
    "exc_status": "Active",
    "traded_date": "Dec 04, 2025",
    "traded_date_str": "2025 12 04",
    "score": "",
    "scoreText": "",
    "Live": 0,
    "market_time": 0,
    "is_blur": 1,
    "is_blur_class": "blur-registerF-score-header",
    "is_blur_url": "https://www.marketsmojo.com/mojofeed/register?redirect=/stocks-analysis/optimizerx-corp-1158609-210&utm_source=Spage_Header_Score",
    "mojoone": {
      "ismore": 0
    }
  },
  "news": {
    "results": [
      {
        "title": "OptimizeRx Corp. Hits New 52-Week High of $21.99, Up 90% Yearly",
        "link": "https://www.marketsmojo.com/news/stocks-in-action/optimizerx-corp-hits-new-52-week-high-of-2199-up-90-yearly-3649220",
        "imagepath": "https://i.marketsmojo.com/newsimg/2025/10/OptimizeRxCorp_priceRelatedfactors_3649220.png",
        "date": "2025-10-27 16:44:46",
        "description": "OptimizeRx Corp. achieved a new 52-week high of USD 21.99 on October 24, 2025, reflecting a substantial increase in stock performance over the past year. The company, with a market capitalization of USD 340 million, remains unprofitable and focuses on growth, maintaining a low debt-to-equity ratio."
      },
      {
        "title": "OptimizeRx Corp. Hits New 52-Week High of $20.66, Up 79.82%",
        "link": "https://www.marketsmojo.com/news/stocks-in-action/optimizerx-corp-hits-new-52-week-high-of-2066-up-7982-3585993",
        "imagepath": "https://i.marketsmojo.com/newsimg/2025/10/OptimizeRxCorp_priceRelatedfactors_3585993.png",
        "date": "2025-10-01 16:31:41",
        "description": "OptimizeRx Corp. has achieved a new 52-week high, reflecting a significant performance improvement over the past year. The company, with a market capitalization of USD 340 million, operates in a competitive sector and maintains a low debt-to-equity ratio, despite being a loss-making entity."
      },
      {
        "title": "OptimizeRx Corp. Hits New 52-Week High of $19.47, Up 67.19% Year-Over-Year",
        "link": "https://www.marketsmojo.com/news/stocks-in-action/optimizerx-corp-hits-new-52-week-high-of-1947-up-6719-year-over-year-3565216",
        "imagepath": "https://i.marketsmojo.com/newsimg/2025/9/OptimizeRxCorp_priceRelatedfactors_3565216.png",
        "date": "2025-09-24 13:14:41",
        "description": "OptimizeRx Corp. achieved a new 52-week high of USD 19.47 on September 23, 2025, reflecting strong performance in the software products industry. The company has seen significant growth over the past year, despite being unprofitable, and maintains a low debt-to-equity ratio, indicating financial stability."
      },
      {
        "title": "Is OptimizeRx Corp. technically bullish or bearish?",
        "link": "https://www.marketsmojo.com/news/stocks-in-action/is-optimizerx-corp-technically-bullish-or-bearish-3545757",
        "imagepath": "",
        "date": "2025-09-20 19:17:54",
        "description": "As of 12 September 2025, the technical trend for OptimizeRx Corp. has changed from bullish to mildly bullish. The weekly MACD is bullish, while the monthly MACD is mildly bullish. Bollinger Bands indicate a bullish stance for both weekly and monthly periods. However, the KST shows a mildly bearish signal on the weekly timeframe, and Dow Theory is mildly bearish on the weekly but mildly bullish on the monthly. The daily moving averages are bullish, suggesting short-term strength.\n\nIn terms of performance, OptimizeRx has significantly outperformed the S&P 500 year-to-date with a return of 289.30% compared to the S&P's 12.22%, and over the past year, it has returned 146.35% versus the S&P's 17.14%. Overall, the current technical stance is mildly bullish, driven primarily by the bullish signals from the MACD and Bollinger Bands, despite some mixed indicators in the KST and Dow Theory...."
      },
      {
        "title": "Is OptimizeRx Corp. overvalued or undervalued?",
        "link": "https://www.marketsmojo.com/news/stocks-in-action/is-optimizerx-corp-overvalued-or-undervalued-3542433",
        "imagepath": "",
        "date": "2025-09-20 17:52:39",
        "description": "As of 4 May 2022, OptimizeRx Corp. moved from a fair to a risky valuation grade. The company appears to be overvalued, given its significant negative valuation ratios, including an EV to EBIT of -86.78 and a P/E ratio that is not applicable due to losses. Additionally, its Price to Book Value stands at 2.33, indicating a premium over its book value, which is concerning in the context of its financial performance.\n\nIn comparison to peers, OptimizeRx Corp. has a notably high EV to EBITDA ratio of 271.52, while Blacksky Technology, Inc. has a much lower EV to EBITDA of -67.11, and ReposiTrak, Inc. shows a fair valuation with a P/E of 47.10. The company's recent stock performance has been impressive, with a year-to-date return of 289.30%, significantly outperforming the S&P 500's 12.22% return, but this does not mitigate the underlying valuation concerns...."
      }
    ],
    "total": 10,
    "sid": "1158609",
    "stock_news_url": "https://www.marketsmojo.com/news/optimizerx-corp-1158609"
  },
  "announcements": "",
  "corporate_actions": {
    "msg": "No corporate action Found"
  }
}

News and Views

OptimizeRx Corp. Hits New 52-Week High of $21.99, Up 90% Yearly

2025-10-27 16:44:46

OptimizeRx Corp. achieved a new 52-week high of USD 21.99 on October 24, 2025, reflecting a substantial increase in stock performance over the past year. The company, with a market capitalization of USD 340 million, remains unprofitable and focuses on growth, maintaining a low debt-to-equity ratio.

OptimizeRx Corp. Hits New 52-Week High of $20.66, Up 79.82%

2025-10-01 16:31:41

OptimizeRx Corp. has achieved a new 52-week high, reflecting a significant performance improvement over the past year. The company, with a market capitalization of USD 340 million, operates in a competitive sector and maintains a low debt-to-equity ratio, despite being a loss-making entity.

OptimizeRx Corp. Hits New 52-Week High of $19.47, Up 67.19% Year-Over-Year

2025-09-24 13:14:41

OptimizeRx Corp. achieved a new 52-week high of USD 19.47 on September 23, 2025, reflecting strong performance in the software products industry. The company has seen significant growth over the past year, despite being unprofitable, and maintains a low debt-to-equity ratio, indicating financial stability.

Is OptimizeRx Corp. technically bullish or bearish?

2025-09-20 19:17:54

As of 12 September 2025, the technical trend for OptimizeRx Corp. has changed from bullish to mildly bullish. The weekly MACD is bullish, while the monthly MACD is mildly bullish. Bollinger Bands indicate a bullish stance for both weekly and monthly periods. However, the KST shows a mildly bearish signal on the weekly timeframe, and Dow Theory is mildly bearish on the weekly but mildly bullish on the monthly. The daily moving averages are bullish, suggesting short-term strength. In terms of performance, OptimizeRx has significantly outperformed the S&P 500 year-to-date with a return of 289.30% compared to the S&P's 12.22%, and over the past year, it has returned 146.35% versus the S&P's 17.14%. Overall, the current technical stance is mildly bullish, driven primarily by the bullish signals from the MACD and Bollinger Bands, despite some mixed indicators in the KST and Dow Theory....

Is OptimizeRx Corp. overvalued or undervalued?

2025-09-20 17:52:39

As of 4 May 2022, OptimizeRx Corp. moved from a fair to a risky valuation grade. The company appears to be overvalued, given its significant negative valuation ratios, including an EV to EBIT of -86.78 and a P/E ratio that is not applicable due to losses. Additionally, its Price to Book Value stands at 2.33, indicating a premium over its book value, which is concerning in the context of its financial performance. In comparison to peers, OptimizeRx Corp. has a notably high EV to EBITDA ratio of 271.52, while Blacksky Technology, Inc. has a much lower EV to EBITDA of -67.11, and ReposiTrak, Inc. shows a fair valuation with a P/E of 47.10. The company's recent stock performance has been impressive, with a year-to-date return of 289.30%, significantly outperforming the S&P 500's 12.22% return, but this does not mitigate the underlying valuation concerns....

View All News